ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 126 citations in OpenAlex.
- Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Efficacy and Determinants of Response to HER Kinase Inhibition inCancer discovery · 2020Trial
- HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects.Science China. Life sciences · 2026Review
- Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer.RSC advances · 2026Review
- Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer-Predisposing Factors in Familial Early-Onset Colorectal Cancer.The Kaohsiung journal of medical sciences · 2026Article
- Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer.Breast cancer research : BCR · 2026Review
- Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability.Journal of mammary gland biology and neoplasia · 2026Review
- Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Comprehensive Molecular Docking and Molecular Dynamics Reveal Inhibitors of HER2 L755S, T798I, and T798M based on a Large Database of Curcumin Derivatives.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Genomic profiling and HER2-targeted therapy: a case series of Chinese salivary duct carcinoma patients and its clinical implications.Frontiers in oncology · 2026Article
- Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling.NPJ breast cancer · 2025Article
- Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.Cell genomics · 2025Article
- Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer.Oncology and therapy · 2025Review
- Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.Human vaccines & immunotherapeutics · 2025Article
- Translating genomic insights into therapy: an NGS-based mutation profiling study in breast cancer.Medical oncology (Northwood, London, England) · 2025Article
- High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.Genomics · 2025Article
- Dual membrane receptor degradation via folate receptor targeting chimera.Nature communications · 2025Article
- The role of genetics and epigenetics in breast cancer: A comprehensive review of metastasis, risk factors, and future perspectives.Journal of pharmaceutical analysis · 2025Review
- Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer.Molecular diagnosis & therapy · 2025Review
- Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 2 institutions in 1 country.
Xiaowei XuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Carmine De AngelisLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Kathleen A BurkeDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Agostina NardoneLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Huizhong HuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Lanfang QinLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jamunarani VeeraraghavanLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Vidyalakshmi SethunathLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Laura M HeiserDepartment of Biomedical Engineering and Oregon Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, Oregon.
Nicholas WangDepartment of Biomedical Engineering and Oregon Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, Oregon.
Charlotte K Y NgDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Edward S ChenDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Alexander RenwickDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Tao WangLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Sarmistha NandaLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Martin SheaLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Tamika MitchellLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Mahitha RajendranLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Ian WatersSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Daniel J ZabranskySidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Kenneth L ScottDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, Texas.
Carolina GutierrezLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Chandandeep NagiLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Felipe C GeyerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Gary C ChamnessLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Ben H ParkSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Chad A ShawDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Susan G HilsenbeckLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Mothaffar F RimawiLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Joe W GrayDepartment of Biomedical Engineering and Oregon Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, Oregon.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
C Kent OsborneLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Rachel SchiffLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. rschiff@bcm.edu.
Sidney Kimmel Comprehensive Cancer Center · USBaylor College of Medicine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MUnderstanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2MTUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9MSystems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI GRAY, JOE W. · 2004 to 2014
$27.1MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5MTraining Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7MBiological annotation of TCGA dataU01CA168394 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2012 to 2016
$4.7MIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA069533NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA186784NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA217842NCI NIH HHS U54 CA112970NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM008752
Abstract
PubMed holds no abstract for this paper.
Indexed as
Molecular Targeted TherapyAfatinibAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibMiceMutationQuinazolinesReceptors, EstrogenAfatinibAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibQuinazolinesReceptors, EstrogenTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.